PET imaging of tumour hypoxia

Cancer Imaging. 2006 Oct 31;6(Spec No A):S117-21. doi: 10.1102/1470-7330.2006.9018.

Abstract

Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour progression. Tumour hypoxia can be detected by non-invasive and invasive techniques but the inter-relationships between these remains largely undefined. [18F]Fluoromisonidazole-3-fluoro-1-(2'-nitro-1'-imidazolyl)-2-propanol ([18F]MISO) and Cu-diacetyl-bis(N4-methylthiosemicarbazone (Cu-ATSM)-positron emission tomography (PET), and blood oxygen level-dependent (BOLD)-magnetic resonance imaging (MRI) are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability; PET techniques are the primary focus of this review.

Publication types

  • Review
  • Retracted Publication

MeSH terms

  • Cell Hypoxia*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Misonidazole / analogs & derivatives
  • Misonidazole / pharmacokinetics
  • Neoplasms / blood supply
  • Neoplasms / diagnostic imaging*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Organometallic Compounds / pharmacokinetics
  • Oxygen / blood
  • Positron-Emission Tomography* / methods
  • Radiopharmaceuticals / pharmacokinetics
  • Thiosemicarbazones / pharmacokinetics

Substances

  • Organometallic Compounds
  • Radiopharmaceuticals
  • Thiosemicarbazones
  • copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • fluoromisonidazole
  • Misonidazole
  • Oxygen